Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Azusa Nagao, Shoko Nakazawa, Hideji Hanabusa

ABSTRACT

Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8) infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD patients are often treated with anti-human interleukin-6 (IL6) receptor monoclonal antibodies (tocilizumab), and successful results have been reported. IL-6 plays an important role in the development of both HIV-positive and HIV-negative MCD; however, the efficacy of tocilizumab in HIV-MCD patients is unknown. We herein report the clinical and biologic courses of two HIV-MCD patients treated with tocilizumab. In both cases, a significant and rapid clinical improvement was observed after the first infusion. However, the treatment efficacy was not maintained for a long period, and relapse occurred at 15 and 22 weeks, respectively. Both patients received rituximab and subsequently achieved complete clinical remission. Our report, in addition to data presented in the literature, suggests that tocilizumab could be an initial treatment option in patients with HIV-MCD. More... »

PAGES

10

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1756-8722-7-10

DOI

http://dx.doi.org/10.1186/1756-8722-7-10

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041400506

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24438824


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Castleman Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Interleukin-6", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Ogikubo Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416765.7", 
          "name": [
            "Ogikubo hospital, Imagawa3-1-24, 167-0035, Suginami-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagao", 
        "givenName": "Azusa", 
        "id": "sg:person.0662555350.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662555350.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ogikubo Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416765.7", 
          "name": [
            "Ogikubo hospital, Imagawa3-1-24, 167-0035, Suginami-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakazawa", 
        "givenName": "Shoko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ogikubo Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416765.7", 
          "name": [
            "Ogikubo hospital, Imagawa3-1-24, 167-0035, Suginami-ku, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanabusa", 
        "givenName": "Hideji", 
        "id": "sg:person.0753170035.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753170035.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1182/blood-2011-08-376012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008860657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2013-08-519959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010622505"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.6732", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032629031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2011-09-377705", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033985919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn697", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035320972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-12-4602", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042428537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-147-12-200712180-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073709373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078223794", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8) infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD patients are often treated with anti-human interleukin-6 (IL6) receptor monoclonal antibodies (tocilizumab), and successful results have been reported. IL-6 plays an important role in the development of both HIV-positive and HIV-negative MCD; however, the efficacy of tocilizumab in HIV-MCD patients is unknown. We herein report the clinical and biologic courses of two HIV-MCD patients treated with tocilizumab. In both cases, a significant and rapid clinical improvement was observed after the first infusion. However, the treatment efficacy was not maintained for a long period, and relapse occurred at 15 and 22 weeks, respectively. Both patients received rituximab and subsequently achieved complete clinical remission. Our report, in addition to data presented in the literature, suggests that tocilizumab could be an initial treatment option in patients with HIV-MCD. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1756-8722-7-10", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1039771", 
        "issn": [
          "1756-8722"
        ], 
        "name": "Journal of Hematology & Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "name": "Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases", 
    "pagination": "10", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c53843f6aa3cd377c87c9f889a24b920a1d189f3f29f8fe448720593f8af87db"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24438824"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101468937"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1756-8722-7-10"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041400506"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1756-8722-7-10", 
      "https://app.dimensions.ai/details/publication/pub.1041400506"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000515.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1756-8722-7-10"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1756-8722-7-10'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1756-8722-7-10'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1756-8722-7-10'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1756-8722-7-10'


 

This table displays all metadata directly associated to this object as RDF triples.

148 TRIPLES      21 PREDICATES      48 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1756-8722-7-10 schema:about N2a72a27ba5744d8f83a286bc27826cb5
2 N4665f3d67e94412ca5b20b92d9866bce
3 N4d1c3bc7695344b78e3cc5a0580e4f6e
4 N7e1cb7fb8772450ba47656485cb30e9c
5 N90002b9e95bc49a68a87a70ff219d0e9
6 Nafe52434cf234d359ad809902620a8af
7 Nb5d83023b59c458bb4bf2bc1c653d642
8 Nbc4be9048b714e528d40813841d57b1d
9 Nd012325f9cf7403484090665064ad4da
10 Ndf61ee57fa954dd29ca3498a34e715cc
11 Nf8b45cd4049f4000bea9b275a2710936
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author N21faf6cf5d6046618d54edb4c851d638
15 schema:citation https://app.dimensions.ai/details/publication/pub.1078223794
16 https://doi.org/10.1093/annonc/mdn697
17 https://doi.org/10.1182/blood-2004-12-4602
18 https://doi.org/10.1182/blood-2011-08-376012
19 https://doi.org/10.1182/blood-2011-09-377705
20 https://doi.org/10.1182/blood-2013-08-519959
21 https://doi.org/10.1200/jco.2007.10.6732
22 https://doi.org/10.7326/0003-4819-147-12-200712180-00003
23 schema:datePublished 2014-12
24 schema:datePublishedReg 2014-12-01
25 schema:description Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8) infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD patients are often treated with anti-human interleukin-6 (IL6) receptor monoclonal antibodies (tocilizumab), and successful results have been reported. IL-6 plays an important role in the development of both HIV-positive and HIV-negative MCD; however, the efficacy of tocilizumab in HIV-MCD patients is unknown. We herein report the clinical and biologic courses of two HIV-MCD patients treated with tocilizumab. In both cases, a significant and rapid clinical improvement was observed after the first infusion. However, the treatment efficacy was not maintained for a long period, and relapse occurred at 15 and 22 weeks, respectively. Both patients received rituximab and subsequently achieved complete clinical remission. Our report, in addition to data presented in the literature, suggests that tocilizumab could be an initial treatment option in patients with HIV-MCD.
26 schema:genre research_article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N07879419ea6645b58237df420e355d1a
30 Nd7d2fca3451d4f6e9e7e3096bbe15eba
31 sg:journal.1039771
32 schema:name Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases
33 schema:pagination 10
34 schema:productId N023a13bd0c3d4c9e9d6d885f77c0ff1c
35 N32734cf73fd04bc5b9f5731f6e6f1388
36 N6d9fd97174ad419a809b07b01aa92cfa
37 N856ab48289954b9493ca89d16358476e
38 N86a297d8070344508e1c53efce609912
39 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041400506
40 https://doi.org/10.1186/1756-8722-7-10
41 schema:sdDatePublished 2019-04-10T13:18
42 schema:sdLicense https://scigraph.springernature.com/explorer/license/
43 schema:sdPublisher Ndf0dc6ff0fb445d19b2c8017438f6e76
44 schema:url http://link.springer.com/10.1186%2F1756-8722-7-10
45 sgo:license sg:explorer/license/
46 sgo:sdDataset articles
47 rdf:type schema:ScholarlyArticle
48 N023a13bd0c3d4c9e9d6d885f77c0ff1c schema:name nlm_unique_id
49 schema:value 101468937
50 rdf:type schema:PropertyValue
51 N07879419ea6645b58237df420e355d1a schema:issueNumber 1
52 rdf:type schema:PublicationIssue
53 N0e377bdd00c4404e9712576d6ece71a8 rdf:first sg:person.0753170035.32
54 rdf:rest rdf:nil
55 N145b1845dab54710a7a17e9213e15372 schema:affiliation https://www.grid.ac/institutes/grid.416765.7
56 schema:familyName Nakazawa
57 schema:givenName Shoko
58 rdf:type schema:Person
59 N21faf6cf5d6046618d54edb4c851d638 rdf:first sg:person.0662555350.25
60 rdf:rest Ndce76c63bcba497c9e7910a2b66fdc0a
61 N2a72a27ba5744d8f83a286bc27826cb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Receptors, Interleukin-6
63 rdf:type schema:DefinedTerm
64 N32734cf73fd04bc5b9f5731f6e6f1388 schema:name doi
65 schema:value 10.1186/1756-8722-7-10
66 rdf:type schema:PropertyValue
67 N4665f3d67e94412ca5b20b92d9866bce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Castleman Disease
69 rdf:type schema:DefinedTerm
70 N4d1c3bc7695344b78e3cc5a0580e4f6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Male
72 rdf:type schema:DefinedTerm
73 N6d9fd97174ad419a809b07b01aa92cfa schema:name readcube_id
74 schema:value c53843f6aa3cd377c87c9f889a24b920a1d189f3f29f8fe448720593f8af87db
75 rdf:type schema:PropertyValue
76 N7e1cb7fb8772450ba47656485cb30e9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Middle Aged
78 rdf:type schema:DefinedTerm
79 N856ab48289954b9493ca89d16358476e schema:name pubmed_id
80 schema:value 24438824
81 rdf:type schema:PropertyValue
82 N86a297d8070344508e1c53efce609912 schema:name dimensions_id
83 schema:value pub.1041400506
84 rdf:type schema:PropertyValue
85 N90002b9e95bc49a68a87a70ff219d0e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Treatment Outcome
87 rdf:type schema:DefinedTerm
88 Nafe52434cf234d359ad809902620a8af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 Nb5d83023b59c458bb4bf2bc1c653d642 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name HIV Infections
93 rdf:type schema:DefinedTerm
94 Nbc4be9048b714e528d40813841d57b1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Time Factors
96 rdf:type schema:DefinedTerm
97 Nd012325f9cf7403484090665064ad4da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Recurrence
99 rdf:type schema:DefinedTerm
100 Nd7d2fca3451d4f6e9e7e3096bbe15eba schema:volumeNumber 7
101 rdf:type schema:PublicationVolume
102 Ndce76c63bcba497c9e7910a2b66fdc0a rdf:first N145b1845dab54710a7a17e9213e15372
103 rdf:rest N0e377bdd00c4404e9712576d6ece71a8
104 Ndf0dc6ff0fb445d19b2c8017438f6e76 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 Ndf61ee57fa954dd29ca3498a34e715cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Antibodies, Monoclonal, Humanized
108 rdf:type schema:DefinedTerm
109 Nf8b45cd4049f4000bea9b275a2710936 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Adult
111 rdf:type schema:DefinedTerm
112 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
113 schema:name Medical and Health Sciences
114 rdf:type schema:DefinedTerm
115 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
116 schema:name Clinical Sciences
117 rdf:type schema:DefinedTerm
118 sg:journal.1039771 schema:issn 1756-8722
119 schema:name Journal of Hematology & Oncology
120 rdf:type schema:Periodical
121 sg:person.0662555350.25 schema:affiliation https://www.grid.ac/institutes/grid.416765.7
122 schema:familyName Nagao
123 schema:givenName Azusa
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662555350.25
125 rdf:type schema:Person
126 sg:person.0753170035.32 schema:affiliation https://www.grid.ac/institutes/grid.416765.7
127 schema:familyName Hanabusa
128 schema:givenName Hideji
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753170035.32
130 rdf:type schema:Person
131 https://app.dimensions.ai/details/publication/pub.1078223794 schema:CreativeWork
132 https://doi.org/10.1093/annonc/mdn697 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035320972
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1182/blood-2004-12-4602 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042428537
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1182/blood-2011-08-376012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008860657
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1182/blood-2011-09-377705 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033985919
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1182/blood-2013-08-519959 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010622505
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1200/jco.2007.10.6732 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032629031
143 rdf:type schema:CreativeWork
144 https://doi.org/10.7326/0003-4819-147-12-200712180-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073709373
145 rdf:type schema:CreativeWork
146 https://www.grid.ac/institutes/grid.416765.7 schema:alternateName Ogikubo Hospital
147 schema:name Ogikubo hospital, Imagawa3-1-24, 167-0035, Suginami-ku, Tokyo, Japan
148 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...